Provista Diagnostics is focused on developing world-class diagnostics for indications in breast and gynecological cancers. When used in combination with standard of care, Provista's blood-based diagnostic tests provide real-time actionable results to improve the accuracy of cancer detection.
Read More
Provista’s proprietary ProteoMark® Technology combines multiple Serum Protein Biomarkers and Tumor Associated Autoantibodies, with patient clinical data, to yield highly accurate diagnostic tests for women’s cancers.
Read More
Provista is developing a robust pipeline of diagnostic blood tests to address unmet needs in women’s cancers including breast, ovarian, endometrial and HPV-associated cancers.
Read More
Diagnostic Dilemma
Dense breast tissue is normal and common among woman and it refers to the appearance of breast tissue on a mammogram. Dense tissue appears white on a mammogram similar to both benign and cancerous lumps leading to both false negative and false positive results.
Read More


Sign Up for E-News
June 2, 2016

June 2, 2016

Provista Diagnostics Announces Positive Trial Results Assessing the Use of Videssa® Breast to Detect Breast Cancer Findings from Trial’s Second Cohort Replicate Prior Results New York – June 2, 2016 – Provista Diagnostics, a company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced […]
May 25, 2016

May 24, 2016

Provista Diagnostics to Present at The 2016 BIO International Convention NEW YORK, NY – May 24, 2016 – Provista Diagnostics, Inc., today announces that David Reese, Ph.D., President and Chief Executive Officer, will deliver a corporate overview at the 2016 BIO International Convention,taking place June 6-9, 2016 at the Moscone […]
April 14, 2016

2016 American Society of Breast Surgeons

2016 American Society of Breast Surgeons Dates: Thursday, April 14 – Saturday, April 16 Location: Dallas, TX – Hilton Anatole Website: breastsurgeons.org Exhibitor Booth: 433